Bone marrow hypermetabolism on18F-FDG PET as a survival prognostic factor in non-small cell lung cancer

Journal of Nuclear Medicine

Volumn 47, Issue 4, 2006, Pages 559-565

  Prévost, Sylvain ^a   Boucher, Luc ^b   Larivée, Pierre ^a   Boileau, Robert ^a   Bénard, François ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Bone marrow; Lung cancer; PET; Prognosis; Standardized uptake value; Survival

Indexed keywords

ALBUMIN; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; LACTATE DEHYDROGENASE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HAZARD RATIO; HUMAN; HYPERCALCEMIA; HYPERMETABOLISM; IMAGING; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; THROMBOCYTOPENIA; UNIVARIATE ANALYSIS; ANALYSIS OF VARIANCE; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; THROMBOCYTOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BONE MARROW; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HYPERCALCEMIA; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOCYTOSIS;

EID: 33745113576     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
2. Eschmann SM, Friedel G, Paulsen F, et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging. 2002;29:804-808.
3. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
4. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037-1057.
5. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases - Leuven Lung Cancer Group. Chest. 1997;112:1480-1486.
6. 18F]FDG positron emission tomography (PET). Thorax. 1997;52:438-441.
7. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-809.
8. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-118.
9. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 2001;120:521-527.
10. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
11. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918-924.
12. 18F-fluoro-2-deoxy-glucose- positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases - Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
13. 18F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425-428.
14. 18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;23:865-870.
15. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39-45.
16. 18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
17. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260.
18. Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707-714.
19. Boucher L, Benard F, Rijo J, et al. Increased bone marrow metabolic activity on FDG-PET in patients with pulmonary malignancies [abstract]. J Nucl Med. 2000;41(suppl):P294.
20. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138:644-650.
21. Hirsch FR, Hansen HH. Bone marrow involvement in small cell anaplastic carcinoma of the lung: prognostic and therapeutic aspects. Cancer. 1980;46:206-211.
22. Kimura H, Yamaguchi Y, Sun L, Iwagami S, Sugita K. Establishment of large cell lung cancer cell lines secreting hematopoietic factors inducing leukocytosis and thrombocytosis. Jpn J Clin Oncol. 1992;22:313-319.
23. Choi JH, Kim HC, Lim HY, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001;33:171-179.
24. Ascensao JL, Oken MM, Ewing SL, Goldberg RJ, Kaplan ME. Leukocytosis and large cell lung cancer: a frequent association. Cancer. 1987;60:903-905.
25. Costantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990;64:501-505.
26. Engan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol. 1990;29:151-154.
27. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9:1826-1830.
28. O'Byrne KJ, Cox G, Swinson D, et al. Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer. 2001;34(suppl 2):S83-S89.
29. Sculier JP, Paesmans M, Libert P, et al. Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party [in French]. Rev Mal Respir. 1997;14:445-449.
30. Ray P, Quantin X, Grenier J, Pujol JL. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev. 1998;22:293-304.
31. Pedersen LM, Milman N. Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. Oncol Rep. 2003;10:213-216.
32. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001;92:2399-2405.
33. Takeuchi R, Kasagi K, Ohta H, Konishi J. Diffuse bony uptake of thallium-201-chloride in the granulocyte colony-stimulating factor-producing lung carcinoma. J Nucl Med. 1998;39:241-243.
34. Osaki T, Oyama T, Inoue M, et al. Molecular biological markers and micrometastasis in resected non-small-cell lung cancer: prognostic implications. Jpn J Thorac Cardiovasc Surg. 2001;49:545-551.
35. Passlick B, Kubuschok B, Izbicki JR, Thetter O, Pantel K. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg. 1999;68:2053-2058.
36. Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996;347:649-653.
37. Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol. 2002;20:2930-2936.